All Stories

  1. Relative Risk of Breast Cancer Associated With Prolactin-Increasing Antipsychotic Use
  2. Non-adherence to mood stabilizers and antipsychotics among persons with bipolar disorder – A nationwide cohort study
  3. β2-Adrenoceptor Agonists in Asthma or Chronic Obstructive Pulmonary Disease and Risk of Parkinson’s Disease: Nested Case-Control Study
  4. Real-world effectiveness of antidepressant use in persons with schizophrenia: within-individual study of 61,889 subjects
  5. Safety of Antipsychotic Polypharmacy Versus Monotherapy in a Nationwide Cohort of 61,889 Patients With Schizophrenia
  6. Association of pharmacological treatments and real‐world outcomes in borderline personality disorder
  7. Cohort profile: SUPER-Finland – the Finnish study for hereditary mechanisms of psychotic disorders
  8. Functional Characterization of Six SLCO1B1 (OATP1B1) Variants Observed in Finnish Individuals with a Psychotic Disorder
  9. Association of Treatment-Resistant Depression With Patient Outcomes and Health Care Resource Utilization in a Population-Wide Study
  10. Associations Between Polygenic Risk Score Loading, Psychosis Liability, and Clozapine Use Among Individuals With Schizophrenia
  11. Association of Pharmacological Treatments and Hospitalization and Death in Individuals With Amphetamine Use Disorders in a Swedish Nationwide Cohort of 13 965 Patients
  12. Psychotic depression and deaths due to suicide
  13. Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosis
  14. Validation of the collaborative outcomes study on health and functioning during infection times (COH-FIT) questionnaire for adults
  15. Factors and their weight in reducing life expectancy in schizophrenia
  16. Antipsychotic Use and Risk of Low-Energy Fractures in People With Schizophrenia: A Nationwide Nested Case-Control Study in Finland
  17. Mortality in psychotic depression: 18-year follow-up study
  18. Twenty‐year medication use trends in first‐episode bipolar disorder
  19. Women with Schizophrenia-Spectrum Disorders After Menopause: A Vulnerable Group for Relapse
  20. Mu-opioid receptor system modulates responses to vocal bonding and distress signals in humans
  21. Real‐world effectiveness of mood stabilizer use in schizophrenia
  22. Allopurinol, dipyridamole and calcium channel blockers in the treatment of bipolar disorder – A nationwide cohort study
  23. Associations between antipsychotic use, substance use and relapse risk in patients with schizophrenia: real-world evidence from two national cohorts
  24. Comparative effectiveness of mood stabilizers and antipsychotics in the prevention of hospitalization after lithium discontinuation in bipolar disorder
  25. Healthcare utilization, costs, and productivity losses in treatment-resistant depression in Finland – a matched cohort study
  26. Clozapine and the risk of haematological malignancies – Authors' reply
  27. Courses of treatment and risk factors for treatment-resistant depression in Finnish primary and special healthcare: A nationwide cohort study
  28. Real-world effectiveness studies of low doses of antipsychotics – Authors' reply
  29. Differences in psychosocial functioning between psychotic disorders in the Finnish SUPER study
  30. Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia
  31. Mortality in people with schizophrenia: a systematic review and meta‐analysis of relative risk and aggravating or attenuating factors
  32. Long-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland
  33. Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends
  34. Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders
  35. Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study
  36. Aberrant motor contagion of emotions in psychopathy and high-functioning autism
  37. Female Psychopathy and Mortality
  38. Primary Nonadherence to Antipsychotic Treatment Among Persons with Schizophrenia
  39. Clinical and societal burden of incident major depressive disorder: A population‐wide cohort study in Stockholm
  40. Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials
  41. Implementation of CYP2D6 copy-number imputation panel and frequency of key pharmacogenetic variants in Finnish individuals with a psychotic disorder
  42. Real‐world effectiveness of pharmacological treatments of opioid use disorder in a national cohort
  43. The collaborative outcomes study on health and functioning during infection times in adults (COH-FIT-Adults): Design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic
  44. Brain structural alterations in autism and criminal psychopathy
  45. The iPSC perspective on schizophrenia
  46. Contribution of astrocytes to familial risk and clinical manifestation of schizophrenia
  47. Switches and early discontinuations of antidepressant medication in young adults with depression
  48. Exploring the relation between high-activity COMT Val158Met genotype and psychopathy in male offenders
  49. Correspondence regarding De Girolamo et al., 2021 ‘A multinational case–control study comparing forensic and non-forensic patients with schizophrenia spectrum disorders: the EU-VIORMED project’
  50. Reaction Time and Visual Memory in Connection to Hazardous Drinking Polygenic Scores in Schizophrenia, Schizoaffective Disorder and Bipolar Disorder
  51. Clozapine, Long-Acting Injectables (and Polypharmacy?) Superior in U.S. and International Registries
  52. Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland
  53. Reaction Time and Visual Memory in Connection to Alcohol Use in Persons with Bipolar Disorder
  54. Associations of age, sex, sexual abuse, and genotype with monoamine oxidase a gene methylation
  55. Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study
  56. Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
  57. Antipsychotic discontinuation: mind the patient and the real-world evidence
  58. Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study
  59. Continuity of antipsychotic medication use among migrant and Finnish-born populations with a psychotic disorder: a register-based study
  60. Molecular signaling pathways underlying schizophrenia
  61. Reaction Time and Visual Memory in Connection with Alcohol Use in Schizophrenia and Schizoaffective Disorder
  62. Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort
  63. HLA-DQB1 6672G>C (rs113332494) is associated with clozapine-induced neutropenia and agranulocytosis in individuals of European ancestry
  64. Brain Basis of Psychopathy in Criminal Offenders and General Population
  65. Hip Fracture Risk in Antiepileptic Drug Initiators and Non-Initiators with Alzheimer’s Disease
  66. Registry-based studies: What they can tell us, and what they cannot
  67. Incidence of schizophrenia and influence of prenatal and infant exposure to viral infectious diseases
  68. Changes in the metabolic profile of human male postmortem frontal cortex and cerebrospinal fluid samples associated with heavy alcohol use
  69. Morbidity and mortality in schizophrenia with comorbid substance use disorders
  70. Voluntary patient safety incidents reporting in forensic psychiatry—What do the reports tell us?
  71. Long-Term Real-World Effectiveness of Pharmacotherapies for Schizoaffective Disorder
  72. Effectiveness of pharmacotherapies for delusional disorder in a Swedish national cohort of 9076 patients
  73. Adenosine modulators and calcium channel blockers as add-on treatment for schizophrenia
  74. Risk of labour market marginalisation among young refugees and non-refugee migrants with common mental disorders
  75. Real‐world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation‐wide cohort of 125 556 patients
  76. Long-Term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study
  77. Antipsychotic use among persons with schizophrenia in Sweden and Finland, trends and differences
  78. Rejoinder to rejoinder to commentary
  79. Suicide mortality and use of psychotropic drugs in patients hospitalized due to bipolar disorder: A Finnish nationwide cohort study
  80. Employment among people with schizophrenia or bipolar disorder: A population‐based study using nationwide registers
  81. Medication management of antipsychotic treatment in schizophrenia—A narrative review
  82. Causes of death in a nationwide cohort of community-dwellers with Alzheimer’s disease
  83. P.810Real-world effectiveness of mood stabilizer use in persons with schizophrenia
  84. Incidence of and Characteristics Associated With Long-term Benzodiazepine Use in Finland
  85. Commentary on Robert Whitaker's viewpoint
  86. Detection of medications associated with Alzheimer's disease using ensemble methods and cooperative game theory
  87. Corrigendum to “Monoamine oxidase A genotype and methylation moderate the association of maltreatment and aggressive behaviour” [Behav. Brain Res. 382 (2020) 112476]
  88. Psychosis relapse during treatment with long-acting injectable antipsychotics in individuals with schizophrenia-spectrum disorders: an individual participant data meta-analysis
  89. Comparative Effectiveness of Antipsychotics for Risk of Attempted or Completed Suicide Among Persons With Schizophrenia
  90. Length of Hospital Stay for Hip Fracture and 30-Day Mortality in People With Alzheimer’s Disease: A Cohort Study in Finland
  91. Medication Use and Health Care Utilization After a Cost-sharing Increase in Schizophrenia
  92. Persistence of Antipsychotic Use After Clozapine Discontinuation: A Real‐World Study Across Antipsychotics
  93. Antiepileptic drug use and mortality among community-dwelling persons with Alzheimer disease
  94. Risk and risk factors for disability pension among patients with treatment resistant depression– a matched cohort study
  95. The clinical course of schizophrenia in women and men—a nation-wide cohort study
  96. T208. EFFECTIVENESS OF PHARMACOLOGICAL THERAPIES FOR DELUSIONAL DISORDER
  97. Monoamine oxidase A genotype and methylation moderate the association of maltreatment and aggressive behaviour
  98. A Systematic Literature Review of Neuroimaging of Psychopathic Traits
  99. Asthma and Chronic Obstructive Pulmonary Disease as a Comorbidity and Association with the Choice of Antidementia Medication Among Persons with Alzheimer’s Disease
  100. Prevalence of cardiovascular drug use before and after diagnosis of Alzheimer's disease
  101. Health and work disability outcomes in parents of patients with schizophrenia associated with antipsychotic exposure by the offspring
  102. Use of antidepressants and mood stabilizers in persons with first-episode schizophrenia
  103. 20‐year follow‐up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)
  104. In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine
  105. The Risk of Head Injuries Associated With Antipsychotic Use Among Persons With Alzheimer's disease
  106. Opioid Use After Hospital Care due to Hip Fracture Among Community-Dwelling Persons With and Without Alzheimer’s Disease
  107. Accumulation of Hospital Days Among Antipsychotic Initiators With Alzheimer's Disease
  108. Metformin and Risk of Alzheimer’s Disease Among Community-Dwelling People With Diabetes: A National Case-Control Study
  109. Correction: Neurobiological roots of psychopathy
  110. Substance Abuse and Excessive Mortality Among Forensic Psychiatric Patients: A Finnish Nationwide Cohort Study
  111. Sex-specific transcriptional and proteomic signatures in schizophrenia
  112. Neurobiological roots of psychopathy
  113. Predictors of high hospital care and medication costs and cost trajectories in community-dwellers with Alzheimer’s disease
  114. Cortical structure abnormalities in females with conduct disorder prior to age 15
  115. Adherence to psychotropic medication in completed suicide in Sweden 2006–2013: a forensic-toxicological matched case-control study
  116. Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study
  117. Hospital-Treated Pneumonia Associated with Opioid Use Among Community Dwellers with Alzheimer’s Disease
  118. Antiepileptic Drugs and Accumulation of Hospital Days Among Persons With Alzheimer's Disease
  119. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia
  120. Increased [³H]quisqualic acid binding density in the dorsal striatum and anterior insula of alcoholics: A post-mortem whole-hemisphere autoradiography study
  121. Long-term thiazide use and risk of low-energy fractures among persons with Alzheimer’s disease—nested case-control study
  122. Changes in patient safety culture: A patient safety intervention for Finnish forensic psychiatric hospital staff
  123. Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review
  124. Trajectories of sickness absence, disability pension and unemployment in young immigrants with common mental disorders
  125. Antiepileptic Drug Use Is Associated with an Increased Risk of Pneumonia Among Community-Dwelling Persons with Alzheimer’s Disease-Matched Cohort Study
  126. Incidence of head injury and traumatic brain injury among people with Alzheimer’s disease
  127. Manifesto for an international digital mental health network
  128. Risk of Treatment Failure: Response to Ghosh and Noble
  129. Associations of Psychopathic Traits With Local and Global Brain Network Topology in Young Adult Women
  130. Response to the editorial on antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia
  131. Concomitant use of benzodiazepines and opioids in community‐dwelling older people with or without Alzheimer's disease—A nationwide register‐based study in Finland
  132. Duration of new antidepressant use and factors associated with discontinuation among community-dwelling persons with Alzheimer’s disease
  133. Comorbid opioid use is undertreated among forensic patients with schizophrenia
  134. Psychotropic drugs use and psychotropic polypharmacy among persons with Alzheimer's disease
  135. Incidence and prevalence of antiepileptic drugs use in persons with Alzheimer's disease.
  136. Systemic Estrogen Use and Discontinuation After Alzheimer’s Disease Diagnosis in Finland 2005–2012: A Nationwide Exposure-Matched Cohort Study
  137. Incident opioid use and risk of hip fracture among persons with Alzheimer disease: a nationwide matched cohort study
  138. Antipsychotic Use and the Risk of Initiating Medication for Benign Prostate Hyperplasia in Persons With Alzheimer Disease
  139. Antiepileptic Drug Use and the Risk of Stroke Among Community‐Dwelling People With Alzheimer Disease: A Matched Cohort Study
  140. Burden for Parents of Patients With Schizophrenia—A Nationwide Comparative Study of Parents of Offspring With Rheumatoid Arthritis, Multiple Sclerosis, Epilepsy, and Healthy Controls
  141. Risk of Treatment Failure: Response to Czobor and Volavka
  142. 20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia
  143. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia
  144. Hospitalization after Oral Antibiotic Initiation in Finnish Community Dwellers with and without Alzheimer’s Disease: Retrospective Register-Based Cohort Study
  145. Mortality in schizophrenia: 30‐year nationwide follow‐up study
  146. The risk of Alzheimer's disease associated with benzodiazepines and related drugs: a nested case–control study
  147. Editorial: let's take a break from studying the PPI‐fracture association—Authors’ reply
  148. Trends in the long‐term use of benzodiazepine anxiolytics and hypnotics: A national register study for 2006 to 2014
  149. Cause-specific mortality in Finnish forensic psychiatric patients
  150. Real-world Effectiveness of Pharmacologic Treatments for the Prevention of Rehospitalization in a Finnish Nationwide Cohort of Patients With Bipolar Disorder
  151. Associations of monoamine oxidase A gene first exon methylation with sexual abuse and current depression in women
  152. Comparison of dispensed medications and forensic‐toxicological findings to assess pharmacotherapy in the Swedish population 2006 to 2013
  153. Use of Antiepileptic Drugs and Dementia Risk—an Analysis of Finnish Health Register and German Health Insurance Data
  154. Impact of opioid initiation on antipsychotic and benzodiazepine and related drug use among persons with Alzheimer's disease
  155. Proton pump inhibitor use and risk of hip fractures among community‐dwelling persons with Alzheimer's disease—a nested case‐control study
  156. Initiation and long‐term use of benzodiazepines and Z‐drugs in bipolar disorder
  157. Platelet monoamine oxidase activity and interpersonal violence in male suicide attempters
  158. Associations Between MAOA‐uVNTR Genotype, Maltreatment, MAOA Methylation, and Alcohol Consumption in Young Adult Males
  159. Amygdala-orbitofrontal structural and functional connectivity in females with anxiety disorders, with and without a history of conduct disorder
  160. Firesetting and general criminal recidivism among a consecutive sample of Finnish pretrial male firesetters: A register-based follow-up study
  161. Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia—A Nationwide Study With 20-Year Follow-up
  162. Genome-Wide Association Studies of a Broad Spectrum of Antisocial Behavior
  163. No Association Between Proton Pump Inhibitor Use and Risk of Alzheimer’s Disease
  164. Risk of disability pension in first and second generation immigrants: the role of age and region of birth in a prospective population-based study from Sweden
  165. Healthcare use among immigrants and natives in Sweden on disability pension, before and after changes of regulations
  166. Risk of death associated with new benzodiazepine use among persons with Alzheimer disease: A matched cohort study
  167. Nurses’ Views Highlight a Need for the Systematic Development of Patient Safety Culture in Forensic Psychiatry Nursing
  168. De‐escalation techniques used, and reasons for seclusion and restraint, in a forensic psychiatric hospital
  169. Drug exposure in register-based research—An expert-opinion based evaluation of methods
  170. Trajectories and characteristics of work disability before and after acute myocardial infarction
  171. Use of lithium in patients with unipolar depression – Author's reply
  172. Is Alzheimer’s Disease Associated with Previous Opioid Use?
  173. Effects of Scheduled Waiting for Psychotherapy in Patients With Major Depression
  174. Reducing the rehospitalization risk after a manic episode: A population based cohort study of lithium, valproate, olanzapine, quetiapine and aripiprazole in monotherapy and combinations
  175. Risk of head and traumatic brain injuries associated with antidepressant use among community-dwelling persons with Alzheimer’s disease: a nationwide matched cohort study
  176. The Association of Ambient Temperature and Violent Crime
  177. White matter correlates of psychopathic traits in a female community sample
  178. Brain structure abnormalities in young women who presented conduct disorder in childhood/adolescence
  179. Pharmacological treatments and risk of readmission to hospital for unipolar depression in Finland: a nationwide cohort study
  180. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia
  181. Long-term use of proton pump inhibitors among community-dwelling persons with and without Alzheimer’s disease
  182. Hospital-treated mental and behavioral disorders and risk of Alzheimer's disease: A nationwide nested case-control study
  183. Psychopathy and Mortality
  184. Screening approach for identifying candidate drugs and drug‐drug interactions related to hip fracture risk in persons with Alzheimer disease
  185. Incident Use of a Potentially Inappropriate Medication and Hip Fracture in Community-Dwelling Older Persons With Alzheimer’s Disease
  186. Seasonal variation of hospital violence, seclusion and restraint in a forensic psychiatric hospital
  187. Use of benzodiazepines and related drugs is associated with a risk of stroke among persons with Alzheimer’s disease
  188. Risk of pneumonia associated with incident benzodiazepine use among community-dwelling adults with Alzheimer disease
  189. Risk of Alzheimer’s disease among users of postmenopausal hormone therapy: A nationwide case-control study
  190. Antipsychotic Use and the Risk of Hip Fracture Among Community-Dwelling Persons With Alzheimer’s Disease
  191. Regional changes in psychotropic use among Finnish persons with newly diagnosed Alzheimer’s disease in 2005-2011
  192. Risk of Mortality Associated with Antipsychotic Monotherapy and Polypharmacy Among Community-Dwelling Persons with Alzheimer’s Disease
  193. Anticholinergic Exposure and Risk of Pneumonia in Persons with Alzheimer’s Disease: A Nested Case-Control Study
  194. Antidepressant use and risk of hip fractures among community‐dwelling persons with and without Alzheimer's disease
  195. Risk of Hip Fracture in Benzodiazepine Users With and Without Alzheimer Disease
  196. Antipsychotic Use and Risk of Hospitalization or Death Due to Pneumonia in Persons With and Those Without Alzheimer Disease
  197. Comparison of predictors of hip fracture and mortality after hip fracture in community-dwellers with and without Alzheimer’s disease – exposure-matched cohort study
  198. Use of antidementia drugs and risk of pneumonia in older persons with Alzheimer’s disease
  199. A Comparison of Sex Differences in Psychotropic Medication Use in Older People with Alzheimer’s Disease in the US and Finland
  200. Differences in analgesic use in community‐dwelling persons with and without Alzheimer's disease
  201. Risk Factors for Initiation of Potentially Inappropriate Medications in Community-Dwelling Older Adults with and without Alzheimer’s Disease
  202. Long-term use of opioids for nonmalignant pain among community-dwelling persons with and without Alzheimer disease in Finland: a nationwide register-based study
  203. Real‐world effectiveness of antipsychotics
  204. Add-on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first-generation antipsychotics
  205. Agreement between PRE2DUP register data modeling method and comprehensive drug use interview among older persons
  206. The effects of a HTR2B stop codon and testosterone on energy metabolism and beta cell function among antisocial Finnish males
  207. Fire-setting performed in adolescence or early adulthood predicts schizophrenia: a register-based follow-up study of pre-trial offenders
  208. Drug use in persons with and without Alzheimer's disease aged 90 years or more
  209. Genome-wide association study of antisocial personality disorder
  210. Influence of a HTR2B Stop Codon on Glucagon Homeostasis and Glucose Excursion in Non-Diabetic Men
  211. Cohort profile: the Finnish Medication and Alzheimer's disease (MEDALZ) study
  212. Mortality and Cumulative Exposure to Antipsychotics, Antidepressants, and Benzodiazepines in Patients With Schizophrenia: An Observational Follow-Up Study
  213. Increased steroid hormone dehydroepiandrosterone and pregnenolone levels in post-mortem brain samples of alcoholics
  214. Incidence and Duration of Cumulative Bisphosphonate Use among Community-Dwelling Persons with or without Alzheimer’s Disease
  215. Month and Season of Birth as a Risk Factor for Alzheimer’s Disease: A Nationwide Nested Case-control Study
  216. Incidence of antidepressant use in community‐dwelling persons with and without Alzheimer's disease: 13‐year follow‐up
  217. Conduct disorder in females is associated with reduced corpus callosum structural integrity independent of comorbid disorders and exposure to maltreatment
  218. Impulsive alcohol-related risk-behavior and emotional dysregulation among individuals with a serotonin 2B receptor stop codon
  219. Hospital care and drug costs from five years before until two years after the diagnosis of Alzheimer’s disease in a Finnish nationwide cohort
  220. Incidence of antipsychotic use in relation to diagnosis of Alzheimer's disease among community-dwelling persons
  221. Long-term use of benzodiazepines: Definitions, prevalence and usage patterns – a systematic review of register-based studies
  222. The Incidence of Benzodiazepine and Related Drug Use in Persons with and without Alzheimer’s Disease
  223. Prevalence of Drug Combinations Increasing Bleeding Risk Among Warfarin Users With and Without Alzheimer’s Disease
  224. Long-term use of antipsychotics among community-dwelling persons with Alzheimer׳s disease: A nationwide register-based study
  225. Baseline symptom severity predicts serotonin transporter change during psychotherapy in patients with major depression
  226. Lithium is associated with decrease in all-cause and suicide mortality in high-risk bipolar patients: A nationwide registry-based prospective cohort study
  227. Hospital-treated suicide attempts among Finnish fire setters: a follow-up study
  228. Opioid abuse and hospitalization rates in patients with schizophrenia
  229. A Pilot Study of Group Administered Metacognitive Training (MCT) for Schizophrenia Patients in a High-Security Forensic Setting: Subjective Training Success and Health-Related Quality of Life
  230. Decreased [³H]naloxone Binding in the Dentate Gyrus of Cloninger Type 1 Anxiety-Prone Alcoholics: A Postmortem Whole-Hemisphere Autoradiography Study
  231. Long-term use of benzodiazepines and related drugs among community-dwelling individuals with and without Alzheimer’s disease
  232. Factors Associated with Hospitalization for Blood-Borne Viral Infections Among Treatment-Seeking Illicit Drug Users
  233. Hospitalization in a Cohort Seeking Treatment for Illicit Drug Use in Finland
  234. Psychotropic drugs and homicide: A prospective cohort study from Finland
  235. Potential Years of Life Lost Due to Premature Mortality Among Treatment-Seeking Illicit Drug Users in Finland
  236. From prescription drug purchases to drug use periods – a second generation method (PRE2DUP)
  237. Psychopathic traits among a consecutive sample of Finnish pretrial fire-setting offenders
  238. [3H]Ifenprodil binding in post-mortem brains of Cloninger type 1 and 2 alcoholics: A whole-hemisphere autoradiography study
  239. Characteristics of drug-abusing females with and without children seeking treatment in Helsinki, Finland
  240. Basal insulin secretion, PCL-R and recidivism among impulsive violent alcoholic offenders
  241. Mortality of firesetters: A follow-up study of Finnish male firesetters who underwent a pretrial forensic examination in 1973–1998
  242. Predictors for initiation of pharmacological prophylaxis in patients with newly diagnosed bipolar disorder—A nationwide cohort study
  243. Concomitant Use of Acetylcholine Esterase Inhibitors and Urinary Antispasmodics Among Finnish Community-Dwelling Persons With Alzheimer Disease
  244. Increased Metabotropic Glutamate 2/3 Receptor Binding in the Perigenual Anterior Cingulate Cortex of Cloninger Type 2 Alcoholics: A Whole-Hemisphere Autoradiography Study
  245. Antipsychotic Treatment and Mortality in Schizophrenia
  246. High prevalence of psychotropic drug use among persons with and without Alzheimer׳s disease in Finnish nationwide cohort
  247. Patterns and 14-year trends in mortality among illicit drug users in Finland: The HUUTI study
  248. Genetic background of extreme violent behavior
  249. Lower [3H]Citalopram Binding in Brain Areas Related to Social Cognition in Alcoholics
  250. Corrigendum to “Mortality among clients seeking treatment for buprenorphine abuse in Finland” [Drug Alcohol Depend. 133 (2013) 391–397]
  251. Antipsychotic Doses Among Community-Dwelling Persons With Alzheimer Disease in Finland
  252. Antipsychotic Polypharmacy among a Nationwide Sample of Community-Dwelling Persons with Alzheimer's Disease
  253. The C9ORF72 expansion does not affect the phenotype in Nasu-Hakola disease with the DAP12 mutation
  254. Antidementia drug use among community-dwelling individuals with Alzheimer’s disease in Finland
  255. Association of Socio-Demographic Factors, Sick-Leave and Health Care Patterns with the Risk of Being Granted a Disability Pension among Psychiatric Outpatients with Depression
  256. Mortality among forensic psychiatric patients in Finland
  257. Factors associated with buprenorphine compared to amphetamine abuse among clients seeking treatment in Finland
  258. Metacognitive group training for forensic and dangerous non‐forensic patients with schizophrenia: A randomised controlled feasibility trial
  259. AMPA receptors in post-mortem brains of Cloninger type 1 and 2 alcoholics: A whole-hemisphere autoradiography study
  260. Mortality among clients seeking treatment for buprenorphine abuse in Finland
  261. Patient Safety Culture in Two Finnish State-Run Forensic Psychiatric Hospitals
  262. Previous forensic mental examination is a useful marker indicating effective violence relapse prevention among psychotic patients
  263. Cluster-Randomized Controlled Trial of Reducing Seclusion and Restraint in Secured Care of Men With Schizophrenia
  264. Use of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimer’s disease research – the Medication use among persons with Alzheimer’s disease (MEDALZ-2005) study
  265. Endogenous cannabinoids in amygdala and hippocampus in post-mortem brains of Cloninger type 1 and 2 alcoholics
  266. Cavum septum pellucidum and psychopathy
  267. Exome sequence analysis of Finnish patients with clozapine-induced agranulocytosis
  268. mGluR1/5 receptor densities in the brains of alcoholic subjects: A whole-hemisphere autoradiography study
  269. Violent behaviour in a forensic psychiatric hospital in Finland: an analysis of violence incident reports
  270. Coexisting social conditions and health problems among clients seeking treatment for illicit drug use in Finland: The HUUTI study
  271. Clozapine resistance—Augmentation strategies
  272. Atypical nucleus accumbens morphology in psychopathy: Another limbic piece in the puzzle
  273. Decreased GABAA benzodiazepine binding site densities in postmortem brains of Cloninger type 1 and 2 alcoholics
  274. Extended‐release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double‐blind, placebo‐controlled trial
  275. Word List Learning in Patients with Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy
  276. Influence of Serotonin Transporter Gene Polymorphism (5-HTTLPR Polymorphism) on the Relation between Brain 5-HT Transporter Binding and Heart Rate Corrected Cardiac Repolarization Interval
  277. Predictors and mediators of add-on mirtazapine-induced cognitive enhancement in schizophrenia – A path model investigation
  278. Using the HCR-20 to Predict Aggressive Behavior among Men with Schizophrenia Living in the Community: Accuracy of Prediction, General and Forensic Settings, and Dynamic Risk Factors
  279. Twelve-year trend in treatment seeking for buprenorphine abuse in Finland
  280. Relationships between pharmacotherapy-induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first-generation antipsychotics combination trial
  281. Ketamine in treatment-resistant major depression
  282. Methylphenidate in the treatment of amphetamine dependence: a double-blind randomised, placebo-controlled trial
  283. Naltrexone depot implant in the treatment of co-morbid amphetamine and opioid dependence
  284. Sociodemographic Characteristics and Drug Abuse Patterns of Treatment-Seeking Illicit Drug Abusers in Finland, 1997–2008: The Huuti Study
  285. Description of long-term polypharmacy among schizophrenia outpatients
  286. Outcome of patients after market withdrawal of thioridazine: A retrospective analysis in a nationwide cohort
  287. Rorschach assessment of personality functioning in patients with polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy
  288. Exome Sequencing Followed by Large-Scale Genotyping Suggests a Limited Role for Moderately Rare Risk Factors of Strong Effect in Schizophrenia
  289. Whole-hemisphere autoradiography of 5-HT1B receptor densities in postmortem alcoholic brains
  290. Polypharmacy With Antipsychotics, Antidepressants, or Benzodiazepines and Mortality in Schizophrenia
  291. Naltrexone Implant for the Treatment of Polydrug Dependence: A Randomized Controlled Trial
  292. Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia
  293. Reply to Drs. Nauta and van Domburg
  294. Examining the effectiveness of antipsychotic medication in first-episode psychosis
  295. Antipsychotic polypharmacy in clozapine resistant schizophrenia: a randomized controlled trial of tapering antipsychotic co-treatment
  296. The Substance Use among Forensic Psychiatric Patients
  297. The net effect of smoking on healthcare and welfare costs. A cohort study
  298. Toward Molecular Psychotherapy of Depression?
  299. The Patient–Therapist Interaction and the Recognition of Affects during the Process of Psychodynamic Psychotherapy for Depression
  300. Statin usage and all‐cause and disease‐specific mortality in a nationwide study
  301. Erratum: Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia
  302. The place of observational studies in assessing the effectiveness of depot antipsychotics
  303. Cortex and amygdala morphology in psychopathy
  304. A Nationwide Cohort Study of Oral and Depot Antipsychotics After First Hospitalization for Schizophrenia
  305. More evidence on proneurocognitive effects of add-on mirtazapine in schizophrenia
  306. Add‐on mirtazapine improves depressive symptoms in schizophrenia: a double‐blind randomized placebo‐controlled study with an open‐label extension phase
  307. Interrelationship between core interventions and core competencies of forensic psychiatric nursing in Finland
  308. Psychopathy, PCL-R, and MAOA genotype as predictors of violent reconvictions
  309. Psychopathic brain -- an unknown challenge for treatment
  310. Gender differences in brain serotonin transporter availability in panic disorder
  311. Group psychoeducation for long‐term offender patients with schizophrenia: An exploratory randomised controlled trial
  312. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial
  313. Serotonin‐transporter‐linked promoter region polymorphism and serotonin transporter binding in drug‐naïve patients with major depression
  314. Extrapyramidal side-effects and dopamine D2/3receptor binding in substantia nigra
  315. MAOA Alters the Effects of Heavy Drinking and Childhood Physical Abuse on Risk for Severe Impulsive Acts of Violence Among Alcoholic Violent Offenders
  316. Endogenous cannabinoids in post-mortem brains of Cloninger type 1 and 2 alcoholics
  317. EFFECTS OF ADD-ON MIRTAZAPINE ON NEUROCOGNITION IN SCHIZOPHRENIA: AN OPEN LABEL EXTENSION PHASE OF A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY, AND BOTH PHASES
  318. The Intergenerational Cycle of Criminality—Association with Psychopathy*
  319. Seasonal variation of seclusion incidents from violent and suicidal acts in forensic psychiatric patients
  320. Dopamine transporter binding in females with panic disorder may vary with clinical status
  321. Predicting forensic admission among the mentally ill in a multinational setting: A Bayesian modelling approach
  322. Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study
  323. Mortality in patients with schizophrenia – Author's reply
  324. Incidence of cancer and antidepressant medication: Record linkage study
  325. Incidence of cancer and statin usage—Record linkage study
  326. Cardiac repolarization and striatal dopamine transporter function are interrelated
  327. Abnormal hippocampal shape in offenders with psychopathy
  328. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)
  329. Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine
  330. Abnormal Cortical Morphology in Offenders with Psychopathy
  331. Low non-oxidative glucose metabolism and violent offending: An 8-year prospective follow-up study
  332. Recidivistic offending and mortality in alcoholic violent offenders: A prospective follow-up study
  333. Altered hemispheric balance of temporal cortex dopamine D2/3 receptor binding in major depressive disorder
  334. Premorbid personality factors in schizophrenia and bipolar disorder: Results from a large cohort study of male conscripts.
  335. The efficacy of lamotrigine in clozapine-resistant schizophrenia: A systematic review and meta-analysis
  336. Antidepressant use and mortality in Finland: a register-linkage study from a nationwide cohort
  337. Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: A double-blind, randomized, placebo-controlled trial
  338. Effects of MAOA‐Genotype, Alcohol Consumption, and Aging on Violent Behavior
  339. 5-HT1A Receptors in the Frontal Cortical Brain Areas in Cloninger Type 1 and 2 Alcoholics Measured by Whole-Hemisphere Autoradiography
  340. Pharmacotherapy of Methamphetamine Addiction: An Update
  341. Brain anatomy of persistent violent offenders: More rather than less
  342. Midbrain serotonin and striatum dopamine transporter binding in double depression: A one-year follow-up study
  343. Association of serotonin transporter promoter regulatory region polymorphism and cerebral activity to visual presentation of food
  344. Predicting Forensic Admission among the Mentally Ill: A Bayesian Approach
  345. Temporal cortex dopamine D2/3 receptor binding in major depression
  346. Striatal dopaminergic terminals in type 1 and type 2 alcoholics measured with [3H]dihydrotetrabenazine and human whole hemisphere autoradiography
  347. Autoradiographic characterization of α2C‐adrenoceptors in the human striatum
  348. Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia
  349. Characterization of metabolic syndrome among forensic psychiatric inpatients
  350. Antidepressant use and mortality in Finland: A register-linkage study from a nationwide cohort
  351. Cortical dopamine D1 receptors in type 1 and type 2 alcoholics measured with human whole hemisphere autoradiography
  352. Changes in midbrain serotonin transporter availability in atypically depressed subjects after oneyear of psychotherapy
  353. Correlation between the SERT binding densities in hypothalamus and amygdala in cloninger type 1 and 2 alcoholics
  354. Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents
  355. Body size and violent offending among males in the Northern Finland 1966 birth cohort
  356. Amygdala serotonin transporters in alcoholics measured by whole hemisphere autoradiography
  357. A Comparison of General Adult and Forensic Patients with Schizophrenia Living in the Community
  358. Energy substrate metabolism among habitually violent alcoholic offenders having antisocial personality disorder
  359. Real-world effectiveness of pharmacological treatments in schizophrenia
  360. Violent persons with schizophrenia and comorbid disorders: A functional magnetic resonance imaging study
  361. Reduced midbrain serotonin transporter availability in drug-naïve patients with depression measured by SERT-specific [123I] nor-β-CIT SPECT imaging
  362. A Multisite Study of Community Treatment Programs for Mentally Ill Offenders With Major Mental Disorders
  363. Functional COMT Val158Met Polymorphism, Risk of Acute Coronary Events and Serum Homocysteine: The Kuopio Ischaemic Heart Disease Risk Factor Study
  364. Transmission of violent offending and crime across three generations
  365. A Comparison of Aripiprazole, Methylphenidate, and Placebo for Amphetamine Dependence
  366. A Comparison of Aripiprazole, Methylphenidate, and Placebo for Amphetamine Dependence
  367. Antidepressants and the Risk of Suicide, Attempted Suicide, and Overall Mortality in a Nationwide Cohort
  368. Visualization of the cortical dopamine transporter in type 1 and 2 alcoholics with human whole hemisphere autoradiography
  369. Nucleus accumbens serotonin transporters in alcoholics measured by whole-hemisphere autoradiography
  370. PMH23 PREDICTING VIOLENT OFFENDING AMONG MENTALLY ILL IN A MULTINATIONAL SETTING–NAIVE BAYESIAN FUSION AND MODEL MERGING WITH P-COURSE
  371. Midbrain binding of [123I]nor-β-CIT in atypical depression
  372. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study
  373. Midbrain dopamine D2/3 receptor binding in schizophrenia
  374. Glutamatergic drugs for schizophrenia
  375. Fatal Agranulocytosis 4 Years After Discontinuation of Clozapine
  376. P.2.c.016 Antidepressant use and the risk of suicide, attempted suicide and overall mortality in a nation-wide cohort
  377. Lower serotonin transporter binding in caudate in alcoholics
  378. Seasonal variations in [3H]citalopram platelet binding between healthy controls and violent offenders in Finland
  379. The consequences of Conduct Disorder for males who develop schizophrenia: Associations with criminality, aggressive behavior, substance use, and psychiatric services
  380. Premorbid Intellectual Functioning in Bipolar Disorder and Schizophrenia: Results From a Cohort Study of Male Conscripts
  381. Topiramate Add-On in Treatment-Resistant Schizophrenia
  382. Subcritical water as eluent for chromatographic separation of carbohydrates using cation-exchange resins
  383. Visualisation of the cortical dopamine D3 receptors in alcoholics and controls with human whole-hemisphere autoradiography
  384. Effects of Venlafaxine Treatment on Clozapine Plasma Levels in Schizophrenic Patients
  385. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis
  386. Striatal dopamine D1 receptors in type 1 and 2 alcoholics measured with human whole hemisphere autoradiography
  387. An Outcome of Psychodynamic Psychotherapy: A Case Study of the Change in Serotonin Transporter Binding and the Activation of the Dream Screen
  388. Dopamine and alcoholism: neurobiological basis of ethanol abuse
  389. Reduced brain serotonin transporter binding in patients with panic disorder
  390. A controlled study of tryptophan and cortisol in violent offenders
  391. SPECT imaging of serotonin transporter binding in patients with generalized anxiety disorder
  392. Cortical dopamine D2 receptors in type 1 and 2 alcoholics measured with human whole hemisphere autoradiography
  393. Elevated midbrain serotonin transporter availability in mixed mania: a case report
  394. Distribution of 5-HT7 receptors in the human brain: a preliminary autoradiographic study using []SB-269970
  395. THE MEDIAL TEMPORAL LOBE IN ALCOHOLISM AND PSYCHOPATHOLOGY: EVALUATION BY VOLUMETRIC MRI.
  396. MRI volumetry of the vermis and the cerebellar hemispheres in men with schizophrenia
  397. 123I-?-CIT binding and recovery from depression
  398. Brain serotonin 1A receptor binding in bulimia nervosa
  399. Characteristics and circumstances of homicidal acts committed by offenders with schizophrenia
  400. Comorbid Personality Disorders and Substance Use Disorders of Mentally Ill Homicide Offenders: A Structured Clinical Study on Dual and Triple Diagnoses
  401. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial
  402. The amygdala and schizophrenia: a volumetric magnetic resonance imaging study in first-episode, neuroleptic-naive patients
  403. Treatment improves serotonin transporter binding and reduces binge eating
  404. P.3.011 Reduced brain serotonin transporter binding in patients with panic disorder
  405. Dopamine D2 receptors and transporters in type 1 and 2 alcoholics measured with human whole hemisphere autoradiography
  406. Total plasma l‐tryptophan, free l‐tryptophan and competing amino acid levels in a homicidal male adolescent with conduct disorder
  407. Dopamine receptors and transporters in the brain reward circuits of type 1 and 2 alcoholics measured with human whole hemisphere autoradiography☆
  408. Ethanol consumption and DRD2 gene TaqI a polymorphism among socially drinking males
  409. Different effect of age on dopamine transporters in the dorsal and ventral striatum of controls and alcoholics
  410. Alcoholics show altered histaminergic neurotransmission in several cortical areas - Preliminary report
  411. Extrastriatal dopamine D2/3 receptor density and distribution in drug-naive schizophrenic patients
  412. Co-eluent effect in partition chromatography. Rhamnose–xylose separation with strong and weak cation-exchangers in aqueous ethanol
  413. Seasonal variation in specific methods of suicide: a national register study of 20 234 Finnish people
  414. Glutamatergic drugs for schizophrenia
  415. Is occupation relevant in suicide?
  416. Prefrontal volumes in habitually violent subjects with antisocial personality disorder and type 2 alcoholism
  417. Use of Statistical Techniques in Studies of Suicide Seasonality, 1970 to 1997
  418. A volumetric MRI study of the entorhinal cortex in first episode neuroleptic-naive schizophrenia
  419. The quantitative risk of violent crime and criminal offending: a case‐control study among the offspring of recidivistic Finnish homicide offenders
  420. Effect of alcohol abuse on human brain histamine and tele-methylhistamine
  421. Serotonin Transporter Distribution and Density in the Cerebral Cortex of Alcoholic and Nonalcoholic Comparison Subjects: A Whole-Hemisphere Autoradiography Study
  422. Analysis of monoamine oxidase A (MAOA) promoter polymorphism in Finnish male alcoholics
  423. Total serum cholesterol level, violent criminal offences, suicidal behavior, mortality and the appearance of conduct disorder in Finnish male criminal offenders with antisocial personality disorder
  424. Seclusion treatment measures and serum cholesterol levels among Finnish male forensic psychiatric patients
  425. Serum lipid levels and violence among Finnish male forensic psychiatric patients
  426. Impaired Temporal Lobe Processing of Preattentive Auditory Discrimination in Schizophrenia
  427. Dopamine Transporter Density and Novelty Seeking Among Alcoholics
  428. Mortality of antisocial male criminals
  429. Free L -tryptophan plasma levels in antisocial violent offenders
  430. Recidivism Among Serious Violent Crime Offenders in Finland
  431. SPECT and neuropsychological performance in severe depression treated with ECT
  432. Measurement of the Striatal Dopamine Transporter Density and Heterogeneity in Type 1 Alcoholics Using Human Whole Hemisphere Autoradiography
  433. Altered frontal lobe function suggested by source analysis of event-related potentials in impulsive violent alcoholics
  434. Dopamine Transporter in vitro Binding and in vivo Imaging in the Brain
  435. Dopamine Transporter in vitro Binding and in vivo Imaging in the Brain
  436. Reduced serotonin transporter binding in binge eating women
  437. Effects of ageing on serotonin transporters in healthy females
  438. A morphometric MRI study of the hippocampus in first-episode, neuroleptic-naı̈ve schizophrenia
  439. The A1 allele of the D2 dopamine receptor gene is associated with high dopamine transporter density in detoxified alcoholics
  440. Dopamine D2/D3-receptor and transporter densities in nucleus accumbens and amygdala of type 1 and 2 alcoholics
  441. Cluster C personality disorder has no independent effect on striatal dopamine transporter densities in major depression
  442. Mortality of antisocial male criminals
  443. Psychopathy and the posterior hippocampus
  444. Characterization of γ-aminobutyrate type A receptors with atypical coupling between agonist and convulsant binding sites in discrete brain regions
  445. In vivo voltammetry with removable carbon fibre electrodes in freely-moving mice: dopamine release during intracranial self-stimulation
  446. Recidivistic Violent Behavior and Axis I and Axis II Disorders
  447. Patterns of dopamine overflow in mouse nucleus accumbens during intracranial self-stimulation
  448. S19.03 Spet studies on outcome of treatment by psychosocial interventions in depression and hysterical paresthesia
  449. Specific binding and laterality of human extrastriatal dopamine D2/D3 receptors in late onset type 1 alcoholic patients
  450. Forensic Psychiatric Organization in Finland
  451. Suicidal behavior in patients with schizophrenia is related to COMT polymorphism
  452. Ethanol modulates evoked dopamine release in mouse nucleus accumbens: dependence on social stress and dose
  453. Regional cerebral blood flow during exposure to food in obese binge eating women
  454. CYP2A6 genotype and smoking
  455. A volumetric MRI study of the hippocampus in type 1 and 2 alcoholism
  456. Metabolism of [ 123 I]epidepride may affect brain dopamine D 2 receptor imaging with single-photon emission tomography
  457. Association Between the Functional Polymorphism of Catechol‐O‐Methyltransferase Gene and Alcohol Consumption Among Social Drinkers
  458. Association Between the Functional Polymorphism of Catechol-O-Methyltransferase Gene and Alcohol Consumption Among Social Drinkers
  459. Pharmacological Intervention for Preventing Violence Among the Mentally Ill with Secondary Alcohol-And Drug-Use Disorders
  460. Lack of association between the functional variant of the catechol-o-methyltransferase (COMT) gene and early-onset alcoholism associated with severe antisocial behavior
  461. Reversed Hemispheric Asymmetry of Auditory N100m in Schizophrenics
  462. Dopamine-transporter density in nucleus accumbens of type-1 alcoholics
  463. Quantitative MRI of the hippocampus and amygdala in severe depression
  464. Dopamine transporter and D 2 -receptor density in late-onset alcoholism
  465. Erratum to “Mortality among habitually violent offenders”
  466. Iodine-123 labelled PE2I for dopamine transporter imaging: influence of age in healthy subjects
  467. Transient Syncope and ECG Changes Associated With the Concurrent Administration of Clozapine and Diazepam
  468. Outcome of different types of long-term antidepressant treatments: a 3-year follow-up study of 14 182 patients
  469. Pindolol and Major Affective Disorders
  470. Association between low activity serotonin transporter promoter genotype and early onset alcoholism with habitual impulsive violent behavior
  471. Striatal dopamine transporter density in major depression
  472. Dopamine transporter availability and depressive symptoms during alcohol withdrawal
  473. Maternal Smoking During Pregnancy and Risk of Criminal Behavior Among Adult Male Offspring in the Northern Finland 1966 Birth Cohort
  474. Association between the functional variant of the catechol-O-methyltransferase (COMT) gene and type 1 alcoholism
  475. Serum testosterone levels, mental disorders and criminal behaviour
  476. Reply
  477. Mortality among habitually violent offenders
  478. Is a Large Body Size During Childhood a Risk Factor for Later Aggression?
  479. Comparison of Iodine-123 Labelled Nor-β-CIT and β-CIT as Potential Radioligands for Serotonin Transporter Imaging
  480. Schizophrenia and seasonality of admissions: the Northern Finland 1966 birth cohort study
  481. Altered Parallel Auditory Processing in Schizophrenia Patients
  482. Increasing homicide rate in Finland accompanied by decreasing seasonality over the period 1957–95
  483. Chronic pindolol treatment and major affective disorders
  484. Abnormal structure of human striatal dopamine re-uptake sites in habitually violent alcoholic offenders: a fractal analysis
  485. 83 Altered frontal lobe function suggested by erp generator analysis in impulsive violent alcoholics
  486. Fentanyl decreases ?-CIT binding to the dopamine transporter
  487. Imaging the structure of the striatum: a fractal approach to SPECT image interpretation
  488. Seasonal variation in suicide occurrence in Finland
  489. Secular trends in the rates and seasonality of violent and nonviolent suicide occurrences in Finland during 1980–95
  490. Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging
  491. Resersal of cerebral asymmetry in schizophrenia measured with magnetoencephalography
  492. The metabolism of iodine-123 labelled 3-(5-cyclopropyl-1,2,4-oxadiazo-3-yl)-7-iodo-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine (NNC 13-8241) measured in human plasma is only minor
  493. Striatal presynaptic dopamine function in type 1 alcoholics measured with positron emission tomography
  494. The incidence and onset-age of hospitalized bipolar affective disorder in Finland
  495. Schizophrenia, alcohol abuse and violent behaviour
  496. Change in monoamine transporter density related to clinical recovery: A case-control study
  497. Fractal analysis – a new approach in brain receptor imaging
  498. Juvenile mortality, mental disturbances and criminality: a prospective study of the Northern Finland 1966 birth cohort
  499. Parental age gap and child sex ratio—Fact or fiction?
  500. Schizophrenia, Alcohol Abuse, and Violent Behavior: A 26-Year Followup Study of an Unselected Birth Cohort
  501. Iodine-123 labeled nor-?-CIT as a potential tracer for serotonin transporter imaging in the human brain with single-photon emission tomography
  502. Seasonal Variation in the Occurrence of Homicide in Finland
  503. Single-photon emission tomography imaging of monoamine transporters in impulsive violent behaviour
  504. Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: a fractal analysis
  505. Fractal analysis of striatal dopamine re-uptake sites
  506. Fractal analysis of striatal dopamine re-uptake sites
  507. Seasonal variation of homicide occurrence in Finland
  508. Specific major mental disorders and criminality: a 26-year prospective study of the 1966 northern Finland birth cohort
  509. Striatal and extrastriatal imaging of dopamine D 2 receptors in the living human brain with [ 123 I]epidepride single-photon emission tomography
  510. Striatal and extrastriatal imaging of dopamine D2 receptors in the living human brain with [123I]epidepride single-photon emission tomography
  511. Dopamine reuptake site densities in patients with social phobia
  512. Schizophrenia, alcohol abuse and violent behaviour
  513. Psychiatric disorders and violent behavior
  514. The predictors of schizophrenia in the 1966 Northern Finland birth cobort study
  515. Impaired adaptation to external input in impulsive violent alcoholics
  516. Characterization of C-11 or I-123 Labelled β-CIT‐FP and β-CIT‐FE Metabolism Measured in Monkey and Human Plasma. Identification of Two Labelled Metabolites with HPLC
  517. Characterization of C-11 or I-123 Labelled ?-CIT-FP and ?-CIT-FE Metabolism Measured in Monkey and Human Plasma. Identification of Two Labelled Metabolites with HPLC
  518. Forensic psychotherapy
  519. Serotonergic modulation of striatal D2 dopamine receptor binding in humans measured with positron emission tomography
  520. Initial human studies with single-photon emission tomography using iodine-123 labelled 3-(5-cyclopropyl-1,2,4-oxadiazo-3-yl)-7-iodo-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]-benzodiazepine (NNC 13-8241)
  521. Mental Disorders and Homicidal Behavior in Finland
  522. Risk of homicidal behavior among discharged forensic psychiatric patients
  523. Factors associated with homicide recidivism in a 13-year sample of homicide offenders in Finland
  524. Low incidence of mania in northern Finland
  525. Schizophrenia and Homicidal Behavior
  526. Citalopram in the Treatment of Alcoholism: a Double-blind Placebo-controlled Study
  527. Quantitative Risk Assessment of Homicidal Behaviour
  528. Homicidal behaviour and mental disorders
  529. The metabolite pattern of [123I]β-CIT determined with a gradient HPLC method
  530. Drs. Tiihonen and Kuikka Reply
  531. Altered striatal dopamine re-uptake site densities in habitually violent and non-violent alcoholics
  532. Iodine-123 labelledN-(2-fluoroethyl)-2?-carbomethoxy-3?-(4-iodophenyl)nortropane for dopamine transporter imaging in the living human brain
  533. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia
  534. Imaging of serotonin and dopamine transporters in the living human brain
  535. Lipophilic metabolite of [123I]β‐CIT in human plasma may obstruct quantitation of the dopamine transporter
  536. Risk of homicidal behaviour among persons convicted of homicide
  537. Altered cerebral blood flow during hysterical paresthesia
  538. Carbamazepine-induced Changes in Plasma Levels of Neuroleptics
  539. Increase in cerebral blood flow of right prefrontal cortex in man during orgasm
  540. Eltoprazine for aggression in schizophrenia and mental retardation
  541. Long-Term Effects of Bilateral Frontal Lobe Lesions from Neuropsychiatric and Neuroradiological Aspects
  542. Magnetoencephalographic localization of epileptic cortex—impact on surgical treatment
  543. Fast decrement with stimulus repetition in ERPs generated by neuronal systems involving somatosensory SI and SII cortices: Electric and magnetic evoked response recordings in humans
  544. Neuromagnetic mismatch fields to single and paired tones
  545. Eosinophilia associated with clozapine
  546. Magnetoencephalographic 10-Hz rhythm from the human auditory cortex
  547. Reply
  548. Localization of epileptic foci using a large‐area magnetometer and functional brain anatomy
  549. Separate finger representations at the human second somatosensory cortex
  550. Early deflections of cerebral magnetic responses to median nerve stimulation
  551. Evoked responses of human auditory cortex may be enhanced by preceding stimuli
  552. Multichannel detection of magnetic compound action fields of median and ulnar nerves
  553. Paired Tone Presentation Enhances Responses of Human Auditory Cortex to Rare Frequency Changes
  554. Magnetic mu rhythm in man
  555. Evoked and Spontaneous Magnetic Activity of the Human Somatosensory Cortex
  556. Molecular characterization of a Y;15 translocation segregating in a family